Researchers are designing peptides that can be swallowed and still reach specific targets in the body, which could open the door to new precision drugs.
Recap by typeshit. Full story at The News & Observer on MSN.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
A short Philstar Life item on PIONEER 8, a trial of oral semaglutide. The material gives only the title, so tap through for the details.
Patients regained 5.1% of weight after the one-time endoscopic procedure versus 8.2% with sham, keeping about 80% of their GLP-1 weight loss, per trial data.
Experts quoted in the piece suggest the spread of GLP-1 drugs could shape how non-users feel about their own bodies and health.
Loading…